Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

NCT05270057 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

11

Enrollment

OTHER

Sponsor class

Conditions

B-cell Lymphoma
Burkitt Lymphoma

Interventions

DRUG: Etoposide
DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Rituximab
DRUG: Vincristine
DRUG: Prednisone
DRUG: Loncastuximab Tesirine 0.075 mg/kg by IV
DRUG: Loncastuximab tesirine 0.12 mg/kg by IV
DRUG: Loncastuximab tesirine 0.15 mg/kg by IV

Sponsor

Medical College of Wisconsin